Atreca Inc. played its hot cancer immunotherapy hand to amass an oversubscribed $56 million series A, enabling the company to exploit its Immune Repertoire Capture (IRC) technology in a ploy to advance therapies that optimize antitumor immune responses in concert with the use of checkpoint inhibitors and immune activators.